Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
- New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1
- This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1
- Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2
Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people3 and often accompanied by cardiovascular complications.4 People with Type 1 and Type 2 diabetes are 2-4 times more likely than someone without diabetes to develop heart disease, a major cause of death for both groups.5 While heart risks for Type 2 diabetes are well known, there's low awareness about heart complications in people with Type 1 diabetes. Adults with Type 1 diabetes who have had serious low blood sugar episodes are twice as likely to be hospitalized for heart-related issues.6
For people with diabetes, the REFLECT findings suggest that the use of Libre technology could also potentially lead to lower healthcare costs due to the reduction in hospital admissions related to heart complications.
"These results are remarkable, as we see dual benefits from CGM technology in managing diabetes and its associated cardiovascular complications," said one of the lead authors of the studies,
The findings also reveal that the risk of hospitalizations for cardiovascular disease was reduced by 80% among people with Type 1 diabetes with no prior history of cardiovascular disease when using the Libre biowearable technology compared to those who used a traditional blood glucose monitor. For individuals with a prior history of cardiovascular disease, the risk of hospitalizations was reduced by 49%.1
"These data are transformative and show just how valuable FreeStyle Libre technology is for managing both diabetes and heart health, helping millions of people live healthy lives," said
The REFLECT research considered a range of cardiovascular-disease related conditions including non-fatal heart attack, non-fatal stroke, coronary artery disease, heart failure, atrial fibrillation and cardiovascular death – conditions commonly seen in people with diabetes.7
"I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations," said
About REFLECT Studies:
The REFLECT studies, funded by
The studies, published between
About FreeStyle Libre:
About
Connect with us at Abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Product for prescription only; for Important Safety Information, please visit FreeStyleLibre.us.
|
|
|
1 |
Eeg-Olofsson, K., Diabetologia (2025): https://doi.org/10.1007/s00125-025-06438-y |
|
2 |
Nathanson, D., Diabetologia (2024): https://link.springer.com/article/10.1007/s00125-024-06289-z |
|
3 |
|
|
4 |
|
|
5 |
|
|
6 |
|
|
7 |
AHA – Cardiovascular disease and diabetes, accessed |
|
8 |
NDR - Nationella Diabetesregistret, accessed |
|
9 |
Eeg-Olofsson K. Diabetes Care (2024): https: doi.org/10.2337/dc 24-0690 |
|
10 |
Data on file, |
|
11 |
Data on file, |
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbotts-libre-technology-is-first-continuous-glucose-monitor-associated-with-reduced-hospitalizations-for-heart-complications-in-people-with-diabetes-302456611.html
SOURCE